China SXT ended buyers' right to acquire up to $12 million in more shares or share-purchase rights, removing one possible source of added shares. The rest of the offering and securities already issued remain unchanged, so the benefit is limited to this change.
Ending the extra option takes away one path for the company to issue more shares. The rest of the offering remains, and securities already issued are unchanged, so the benefit applies only to this one purchase right.
Follow China SXT Pharmaceuticals, Inc. (SXTC) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for SXTC